Award
NIH Reporter #1R01AI201701-01
Immunomodulatory Blockade of Type 2 Immunity for Severe Coccidioidomycosis
Recipient
National Institute of Allergy and Infectious Diseases (NIAID)
Awarded
August 11, 2026
Identifier
1R01AI201701-01
This award funds a clinical trial led by NIAID to evaluate dupilumab as a treatment for severe coccidioidomycosis, focusing on improving clinical outcomes and understanding immunologic effects.
Description
The project involves a clinical trial testing the efficacy of dupilumab in treating severe coccidioidomycosis. The project aims to determine if dupilumab improves clinical outcomes and to assess its immunologic effects. It is a paradigm shift toward host-directed immunomodulatory therapy for invasive fungal infections.